in this issue
Pharma/Fine Chemicals Roundup – December 6
December 6, 2011 | By DEEPTI RAMESH
CPHI INDIA: DSM SINOCHEM PHARMACEUTICALS FOCUSES ON INORGANIC GROWTH
DSM Sinochem Pharmaceuticals (DSP; Hong Kong), the former DSM Anti-Infectives, is focused on inorganic growth of its business and the partnership with Sinochem (Beijing) provides “access to deals in China”, Bharath Sesha, v.p./Asia Pacific, Mideast and Africa at DSP told CW at the CPhI India exhibition at Mumbai, last week. The company did not disclose further details of the “deals” it is working towards. DSM and Sinochem completed a deal in August 2011 to establish a 50-50 jv for the DSM Anti-Infectives business. Sinochem acquired a 50% stake in DSM Anti-Infectives for €210 million, creating DSP. DSP develops, produces, and sells raw materials, intermediates, and APIs for anti-infectives such as antibiotics; anti-fungals; and APIs for other therapeutic classes such as cholesterol-lowering medicines.
The DSM Anti-Infectives business recorded sales of €347 million ($466 million) in 2010, and DSP is targeting annual sales of €600 million by 2015.
“Growth is happening in [emerging economies] and a large majority of DSP’s sales growth by 2015 will come from countries like China and India,” Sesha says.
RANBAXY LAUNCHES GENERIC VERSION OF LIPITOR – THE TOP SELLING DRUG
The U.S. Food and Drug Administration (FDA) has approved the first generic version of Pfizer’s cholesterol-lowering drug Lipitor - atorvastatin calcium tablets. Ranbaxy Pharmaceuticals (Jacksonville, FL) USA, a subsidiary of Ranbaxy Laboratories (Gurgaon, India) received final approval from the FDA to manufacture and market atorvastatin and has launched the product in the U.S. market on December 1. Lipitor, the top-selling drug, generates annual sales of about $7.89 billion in the U.S., Ranbaxy says.
Ranbaxy has gained approval to make generic atorvastatin calcium tablets in 10 mg, 20 mg, 40 mg, and 80 mg strengths. The drug will be manufactured by Ranbaxy’s Ohm Laboratories subsidiary at New Brunswick, NJ.
VIVIMED ACQUIRES SPANISH API MANUFACTURER
Vivimed Labs (Hyderabad, India) says it has acquired Uquifa (Barcelona, Spain), a manufacturer of active pharmaceutical ingredients (APIs) and pharma intermediates, with manufacturing sites in Spain and Mexico. The acquisition strengthens Vivimed’s footprint in Europe and the Americas, the company says. Uquifa will become the API division of Vivimed and will be investing in new research and development and manufacturing facilities in India.
LONZA SIGNS API MANUFACTURING DEAL WITH ELAN
Biotechnology company Elan (Dublin, Ireland) says it has entered into a manufacturing agreement with Lonza for the supply of the active pharmaceutical ingredient (API) for ELND005, which is being developed by Elan for the treatment of Alzheimer's disease.
U.K. GOVERNMENT OFFERS RELIEF ON ENERGY COSTS AND R&D
By Alex Scott
The U.K. government says it will provide a reported £250 million ($390 million) in tax relief and compensation to energy intensive companies faced with higher costs from its national carbon tax, and also extend its R&D tax credit to larger companies. The two areas of relief for industry were tabled today by the U.K.government as part of a broad package of financial policies in its Autumn Statement.
Pharmaceutical organizations also gave the policy announcement a positive reception. “Extending R&D tax credits to larger firms will encourage pharmaceutical companies to further invest in their own business and in new medicines,” says Stephen Whitehead, CEO of the Association of the British Pharmaceutical Industry (ABPI; London). “Measures aimed at providing the right environment for our industry to thrive play an important part of our success and so we are pleased that government is continuing its support of life sciences,” he says.
ABPI also is banking on further measures to be introduced by the U.K. chancellor George Osborne to assist the pharma sector. “Building on today’s announcement, we are expecting a range of further measures to support the life sciences sector to be announced shortly. It is important these upcoming proposals deliver the reforms that our sector needs if, as is the chancellor’s ambition, the pharmaceutical industry is be a long term driver of economic growth in the U.K.”